Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System increased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 25.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,087 shares of the company's stock after purchasing an additional 7,629 shares during the quarter. California State Teachers Retirement System owned 0.06% of Harmony Biosciences worth $1,276,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $41,000. KBC Group NV increased its position in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after buying an additional 819 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after acquiring an additional 519 shares during the last quarter. Virtus Investment Advisers Inc. acquired a new position in shares of Harmony Biosciences in the fourth quarter worth $124,000. Finally, Summit Investment Advisors Inc. lifted its position in shares of Harmony Biosciences by 34.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock valued at $137,000 after acquiring an additional 1,029 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Trading Up 1.2%

Harmony Biosciences stock traded up $0.43 during trading on Tuesday, reaching $35.85. The company had a trading volume of 424,438 shares, compared to its average volume of 615,322. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock's 50 day moving average price is $31.82 and its two-hundred day moving average price is $34.08. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of 16.99, a PEG ratio of 0.47 and a beta of 0.87.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. The company had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business's quarterly revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.67 EPS. As a group, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HRMY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Mizuho lifted their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. Needham & Company LLC reissued a "buy" rating and set a $49.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, May 6th. UBS Group decreased their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Harmony Biosciences currently has an average rating of "Buy" and an average target price of $53.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.